Hanmi Pharma Seals ₩3.2 Trillion Roche-Genentech Obesity Drug Deal; Analyst Targets Jump 26%

The Quick Take

• Hanmi Pharmaceutical signed a licensing deal worth up to ₩3.2 trillion with Roche Group's Genentech for its muscle-preserving obesity drug candidate
• The deal follows Hanmi's $1B+ Eli Lilly partnership just three months ago, establishing Hanmi as Korea's premier GLP-1 drug pipeline developer
• Kiwoom Securities raised its Hanmi target price from ₩580,000 to ₩730,000 (+25.9%) with a buy recommendation maintained; previous close was ₩540,000
• Illegal cross-border imports of obesity drugs from Japan — priced at ₩13,000 vs Korea's ₩32,000 — surged 3.5x in H1 2026 amid domestic affordability pressure

Hanmi Pharmaceutical's licensing deal with Roche's Genentech unit for a muscle-preserving GLP-1 obesity drug candidate worth up to ₩3.2 trillion marks the company's second major international licensing milestone in three months, following an Eli Lilly partnership earlier in 2026. The rapid succession of deals validates Hanmi's proprietary LAPSCOVERY platform — its long-acting drug delivery technology — as competitive with global GLP-1 innovation. Unlike standard GLP-1 drugs that cause concurrent muscle mass loss, Hanmi's candidate targets the preservation of lean body mass during weight reduction, addressing a key clinical limitation that has concerned endocrinologists and could differentiate it in the crowded obesity drug market.

The market implication extends beyond Hanmi itself. Two successive mega-deals with Eli Lilly and Roche-Genentech establish South Korea as a serious GLP-1 drug development ecosystem, with implications for Korean CDMO/CRO capacity, pharma park investment, and biotech startup valuations. Kiwoom Securities' 25.9% target price increase — from ₩580,000 to ₩730,000 — reflects genuine upward revision of the pipeline's risk-adjusted NPV rather than sentiment alone, given Genentech's rigorous due diligence process. The illegal drug import surge from Japan, where Munjaro and Wegovy are priced at ₩13,000 versus Korea's ₩32,000, reveals a structural affordability and reimbursement issue in the Korean healthcare system that could become a policy flashpoint.

Investors should watch for Genentech's clinical development milestone announcements as the deal converts from licensing fees to phase-dependent payments — the ₩3.2 trillion headline is milestone-contingent, and the pace of Phase I/II trial initiation will determine cash receipt timing for Hanmi. Korean pharma regulatory dynamics at MFDS (Ministry of Food and Drug Safety) for GLP-1 pricing and reimbursement are the domestic policy variable most likely to determine whether illegal import pressure moderates or escalates. The GLP-1 global patent landscape, including Novo Nordisk and Eli Lilly's competitive positioning on muscle-preservation claims, is the sector-wide signal to monitor.

Synthesized from 6 sources.